Novel Compounds for the Prevention and Treatment of Clostridium difficile Infections
Dr. Charles Darkoh has identified and developed novel compounds that may reduce or inhibit toxin production and toxin activity, which directly and selectively targets the cause of C. difficile-associated illness. Dr. Darkoh has further developed potential combination cocktails of these novel compounds which may be used as comprehensive and effective therapeutics for the treatment of both initial and recurrent C. difficile infections. This method of treatment does not affect cell growth and as a result, drug resistance may be greatly reduced due to lack of selective pressure. Furthermore, this approach may promote intestinal homeostasis, which decreases the recovery time and reduce the relapse rates. This novel non-antibiotic treatment option directly targets the cause of the disease and is a promising approach to prevent and treat C. difficile infections.